SHANGHAI ISE ONE III IIAZUI Yin Chena Road Middle hanahai 200120 PR China 上海市通力律师事务所关于深圳微芯生物科技股份有限公司 2021 年股票增值权激励计划作废部分股票增值权相关事宜之 法律意见书 致:深圳微芯生物科技股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受深圳微芯生物科技股份有限公司(以下简 称"微芯生物"或"公司")委托,指派本所陈军律师、郭珣律师(以下合称"本所律师") 作为公司特聘专项法律顾问,根据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委员会(以下简 称"中国证监会")发布的《上市公司股权激励管理办法》(以下简称"《管理办法》")等 法律、行政法规以及其他规范性文件(以下简称"法律、法规以及规范性文件")、《深圳微 芯生物科技股份有限公司章程》(以下简称"《公司章程》")、《深圳微芯生物科技股份有 限公司 2021 年股票增值权激励计划》(以下简称"《股票增值权激励计划》")的有关规定, 就公司 2021 年股票增值权 ...

Core Viewpoint - Microchip Biotech (688321.SH) plans to repurchase shares worth between 10 million to 15 million yuan at a price not exceeding 47.46 yuan per share, intended for employee stock ownership plans or equity incentives [1] Summary by Relevant Categories - **Share Repurchase Plan** - The company intends to repurchase shares valued between 10 million to 15 million yuan [1] - The maximum repurchase price is set at 47.46 yuan per share [1] - **Purpose of Repurchase** - The repurchased shares will be used for employee stock ownership plans or equity incentives [1]

Core Viewpoint - Microchip Biotech (688321.SH) plans to repurchase shares worth between 10 million to 15 million yuan, with a maximum repurchase price of 47.46 yuan per share, intended for employee stock ownership plans or equity incentives [1] Summary by Category - **Company Actions** - The company intends to repurchase shares valued at 10 million to 15 million yuan [1] - The maximum price for the repurchase is set at 47.46 yuan per share [1] - **Purpose of Repurchase** - The repurchased shares will be used for employee stock ownership plans or equity incentives [1]

微芯生物10月31日公告，拟以集中竞价交易方式回购公司股份，回购总金额1000.00万元~1500.00万 元，回购价格不超过47.46元/股。回购股份将用于员工持股计划或者股权激励。回购期限为自董事会审 议通过回购股份方案之日起12个月内。 ...

微芯生物公告称，公司计划以不低于1000万元且不超过1500万元的自有资金及股票回购专项贷款，通过 集中竞价交易方式回购部分A股股份，回购价格不超过47.46元/股。回购的股份将用于员工持股计划或 股权激励。董事会已通过该回购方案，无需提交股东大会审议。公司董事长XIANPINGLU提议回购， 并承诺推动公司尽快召开董事会审议回购股份事项。回购期限为自董事会审议通过之日起12个月内。 (本文来自第一财经) ...

Group 1 - The company Microchip Biotech (SH 688321) announced on October 31 that its 17th meeting of the third board of directors for 2025 was held on October 30, 2025, combining in-person and communication methods [1] - The company reported that for the year 2024, its revenue composition is 97.96% from the pharmaceutical manufacturing industry and 2.04% from other businesses [1] - As of the report, Microchip Biotech has a market capitalization of 12.6 billion yuan [1]

Core Viewpoint - Microchip Biotech (688321.SH) plans to repurchase A-shares using self-owned funds and a special loan, with a total amount between 10 million and 15 million yuan, at a price not exceeding 47.46 yuan per share [1] Group 1 - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] - The board of directors has approved the repurchase plan without needing to submit it for shareholder meeting approval [1] - The repurchase period is set for 12 months from the date of board approval [1]

Group 1 - The company, Microchip Biotech (688321.SH), announced a share repurchase plan aimed at employee stock ownership or equity incentives [1] - The total amount for the share repurchase will be no less than RMB 10 million and no more than RMB 15 million [1] - The maximum repurchase price is set at RMB 47.46 per share [1]

微芯生物公告称，公司拟以集中竞价交易方式回购股份，金额不低于1000万元且不超过1500万元，资金 源于自有资金及专项贷款。回购价不超47.46元/股，数量为21.07万股至31.6万股，占总股本0.05% - 0.08%，用于员工持股计划或股权激励，期限自董事会审议通过起12个月内。截至公告披露日，除持股 5%以上股东博奥生物正履行减持计划外，其余相关方暂无明确增减持计划。本次回购存在价格、用 途、重大事项及监管政策等风险。 ...

Core Viewpoint - Shenzhen MicuRx Pharmaceuticals, Inc. reported a significant revenue growth of 40.12% year-on-year for the first three quarters of 2025, driven by increased sales of its products, particularly Sidaracizumab and Siglec-1 [1] Financial Performance - The company achieved a total revenue of 674 million yuan in the first three quarters [1] - Sales revenue for Sidaracizumab increased by 18.76% year-on-year [1] - Sales revenue for Siglec-1 surged by 136.13% year-on-year [1] Product Development and Strategy - MicuRx Pharmaceuticals has developed a global strategy based on early research in China, leveraging a team of top scientists with extensive experience in relevant fields [1] - The company employs an integrated technology platform that combines AI-assisted design and chemical genomics, facilitating the entire process from basic research to clinical translation [1] - As of June 30, the company has two innovative drugs with multiple indications globally marketed, focusing on five major areas: malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [1]